Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart pacing experiment: three spots better than two?

NCT ID NCT02962791

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether pacing three spots in the heart instead of the usual two could improve cardiac resynchronization therapy (CRT) for people with heart failure. About 30% of patients don't respond well to standard CRT. The trial planned to enroll 36 adults with severe heart failure, but it was terminated early. Researchers measured changes in heart size and function using echocardiography.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cardiac resynchronization therapy with stimulation of 3 ventricular sites (a device procedure)
What this could lead to
If successful, this approach could improve heart function and reduce symptoms for heart failure patients who don't respond to standard pacing.
What could go wrong
The trial was terminated early with only 36 participants, so results are limited. Triple-site pacing may not prove better than standard therapy and could carry additional risks from extra leads.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Oct 2017

Finished

Nov 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient who signed the MEC approved informed consent * Patient older than 18 * Patient with a CRT (CRT-P or D) indication as per ESC guidelines 2013 * Left Ventricular Ejection Fraction (LVEF) ≤ 35% * NYHA class II/III/IV despite optimal medical treatment * Left Bundle Branch Block (LBBB) and QRS ≥ 120 ms (class IA and IB indications) or in the absence of LBBB QRS \> 150 ms (class IIA indication) * De novo implantation * Sinus rhythm Exclusion Criteria: * Permanent supra ventricular tachycardia * Pacing indication for 3rd degree AV block * Impossibility to perform FU at the investigative center * Pregnancy * Adults under legal protection * Heart transplant candidates * Concomitant pathology that may interfere with the study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac resynchronization therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac resynchronization therapy

Contacts and locations

Locations

  • Rouen University Hospital

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.